Syndrome x: Recognition and management of this metabolic disorder in primary care

Nurse Practitioner

Volumn 21, Issue 6, 1996, Pages 74-86

  Minchoff, Lois E ^a   Grandin, Judith A ^b  

^a Brunswick Jefferson Family Practice   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METFORMIN;

ARTERIOSCLEROSIS; HUMAN; HYPERTENSION; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIMARY HEALTH CARE; REVIEW; SYNDROME;

ARTERIOSCLEROSIS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERTENSION; METABOLIC DISEASES; METFORMIN; OBESITY; PRIMARY HEALTH CARE; SYNDROME;

EID: 0030162943     PISSN: 03611817     EISSN: 15388662     Source Type: Journal    
DOI: 10.1080/19966205-199606000-00005     Document Type: Article

References (30)

1. Reaven, G: Role of insulin resistance in human disease. Diabetes 1988;37:1595-607.
2. Wajchenberg, BL, Malerbi DA, Rocha MS, et alt Syndrome X: A syndrome of insulin resistance. Epidemiological and clinical evidence. Diabetes Metab Rev 1994; 10(1): 19-29.
3. DeFronzo R, Bonadonna R, et ah Pathogenesis of NIDDM: A balanced overview. Diabetes Care 1992;15(3):318-53.
4. DeFronzo R, Ferrannini E: Insulin resistance: Multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and adierosclerotic cardiovascular disease. Diabetes Care. 1991; 14(3): 173-87.
5. Nesder J: Assessment of insulin resistance. Sci Am 1994;Sept/Oct:58-67.
6. DcFronzo R: The effect of insulin on renal sodium metabolism: A review with clinical implications. Diabctologia 1981;21:165-171.
7. Lillioja S, Young S, Culter C, et al: Skeletal muscle capillary density and fiber type are possible determinants of in vivo insulin resistance in man. J Clin Invest 1987;80:415-424.
8. Stout R: Insulin and atheroma: 20-year perspective. Diabetes Care 1990;13(6):631-54.
9. Reaven G: Syndrome X: 6 years later. J in Med 1994;236(736)13-22.
10. Martin M, Fuh T, Jeng CY, et al: Insulin resistance, glucose intolerance and hyperinsulinemia in patients with microvascular angina. Metabolism 1993;42(9): 1090-92.
11. Dean JD, Jones CJ, Hutchinson SJ, et al: Hyperinsulinemia and microvascular angina (“syndrome X”). Lancet 1991;337:456-57.
12. Dunaif A: Hyperandrogénie Anovulation (PCOS): A unique disorder of insulin action associated with an increased risk of Non-Insulin-Dependent Diabetes Mellitus. Am J Med 1995;98(1A):33S-39S.
13. Sims E, Danford E, Horton E, et al: Endocrine and metabolic effects of experimental obesity in man. Recent Prog Metab Res 1973;29:457-96.
14. Bonadonna R, Groop L, Kraemer N, et al: Obesity and insulin resistance in man: A dose response study. Metabolism 1990;39(5)·.452-59.
15. Saad F, Knowler C, Pettit J, et al: Sequential changes in serum insulin concentration during development of non-insulin-dependent diabetes. Lancet 1989;1:1356-59.
16. Williams B: Insulin resistance: The shape of things to come. Lancet 1994;344:521-59.
17. Kisselbah A, Peiris A: Biology of regional body fat distribution: Relationship to Non-Insulin Dependent Diabetes Mellitus. Diabetes Metab Rev 1989;5(2):83-109.
18. Schwartz RA: Acanthosis nigricans. J Am Acad Dermatol 1994;31:1-13.
19. Harris MI, Klein R, Wclborn RA, et al: Onset of NIDDM occurs at least 4-7 years before clinical diagnosis. Diabetes Care 1992;15:815-19.
20. Little RR, England JD, Wìcdmcyer HM, et al: Relationship of glycosylated hemoglobin to oral glucose tolerance: Implications for diabetes screening. Diabetes 1988;37:60-64.
21. Melkus G: Type II non-insulin dependent diabetes. Nurs Clin North Am 1993;28:35-43.
22. Manson JA, Nathan DM, Krolewski AS, et al: A prospective study of exercise and incidence of diabetes among U.S. male physicians. JAMA 1992;268(1):63-67.
23. U.S. Department HHS: Healthy People 2000, Washington, D.C.: DHHS, 1991: p. 95.
24. Reaven G: Beyond cholesterol: Why knowing your total cholesterol level is simply not enough. Healdiline 1992;11:2-4.
25. Diabetic Control and Complications Trial Research Group: N Engl J Med 1993;329:14,977-86.
26. Collo M, Johnson J, Kabadi U: Combination sulfonylurea and insulin therapy in NIDDM. Nurse Prac 1993;18:40-48.
27. Nagi DK, Yudkin JS: Effects of metformin on insulin resistance, risk factors for cardiovascular disease and plasminogen activator inhibitor in NIDDM subjects. Diabetes Care 1993; 16(4):621-29.
28. Bailey CJ: Biguanides and NIDDM. Diabetes Care 1992;15:755-72.
29. Weiner I: Diuretics and other agents employed in the mobilization of edema fluid, in Gilman A, Rail T, Nies A, Taylor P: The Pharmacological Basis of Therapeutics, 8th ed. New York, Pergamon Press, 1990, p. 721.
30. Karam J: Type II diabetes and syndrome X: Padiogenesis and glycemic management, Endocrinol Metab Clin Nordi Am 1992;21(2):329-50.